# Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ef99a3b3
Ticker: VOR
Company: Vor Biopharma
Source: Vor Biopharma
Published: 2026-07-02 21:30 EST
## Summary

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune...

## Article Body
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on July 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 71,200 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 15,150 shares of Vor Bio’s common stock to 7 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

The stock options have a ten-year term, and an exercise price of $18.39 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com
## Recent Company News
- 2026-07-07 20:01 EST — [Vor Bio Appoints David Zaccardelli to Board of Directors](https://biopharmsignal.com/news/VOR/vor-bio-appoints-david-zaccardelli-to-board-of-directors-7c744ed5) — Source: Vor Biopharma
- 2026-07-02 21:30 EST — [Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ef99a3b3) — Source: Vor Biopharma
- 2026-06-08 12:31 EST — [Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China](https://biopharmsignal.com/news/VOR/telitacicept-receives-nmpa-approval-for-the-treatment-of-sj-gren-s-disease-in-ch-185b18e7) — Source: Vor Biopharma
- 2026-06-08 12:30 EST — [Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China](https://biopharmsignal.com/news/VOR/telitacicept-receives-nmpa-conditional-approval-for-the-treatment-of-iga-nephrop-59acfea5) — Source: Vor Biopharma
- 2026-06-01 21:00 EST — [Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-955d407c) — Source: Vor Biopharma
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)